7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,079.50

-34.00

-0.83%

75,974.52

-97.41

-0.13%

Crude Oil Dec 26

90.34

-0.18

-0.20%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Delayed Quote USD

Instil Bio, Inc. (TIL)

6.83 -0.16 (-2.29%)

At close: November 6 at 4:00:01 PM EST

Loading Chart for TIL

Chart Range Bar

Interval:

In partnership with ChartIQ

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

Mobilize your Website

View Site in Mobile | Classic

Share by: